FDA Panel Urges Stronger Warnings for Anemia Drugs
2007-05-23
A U.S. Food and Drug Administration advisory panel on Thursday called for new warnings and additional safety studies on anemia drugs commonly used to treat patients undergoing kidney dialysis or chemotherapy.
These medications have been the subject of controversy since some of their dangerous side effects -- including the risk of heart attacks and stroke -- came to light earlier this year. In March, the FDA issued stronger label warnings for the popular drugs.